Accelerate Diagnostics Value Stock - Dividend - Research Selection
Market price: 6,86 USD
Accelerate Diagnostics Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-50.394.000|
|Free cash flow||-51.756.000|
|Liabilities & Shareholders equity||93.425.000|
|Diluted shares outstanding||57.607.900|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||395.190.208,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2013-07-08,1231.000000/1230.000000; 1996-11-19,1.000000/4.000000|
Description of the company
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.